Scientists from Hong Kong created Today, an experimental drug that might protect from the coronavirus and the flu. According to Bloomberg, the 1st trial will include nearly 100 adults.
At least one coronavirus vaccine might be approved for emergency use by the end of the year in America and the EU, at which point at-risk categories of people could be immunized.
Coronavirus
The vaccine has received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and the Hong Kong government. CEPI will also analyze successful vaccines and compare all the research results to identify the best approaches for preventing infection. The Hong Kong trial will have Phase 1 results a few months after its November start date.
On other hand, the infrastructure, know-how, and capacity developed for three ongoing cardiovascular outcomes trials (CVOT) of vaccines against influenza may provide a roadmap for testing novel interventions against COVID-19 in cardiovascular disease patients.
Later, Russia’s State Research Center of Virology and Biotechnology VECTOR revealed, on Friday, the expected date for registering the second Russian Coronavirus vaccine.
The head of the center Rinat Maxotov said that the vaccine clinical trials center were in its early stages last month, indicating that he expected the vaccine to be registered on October 15, according to the “RIA Novosti ” agency.
“Separate clinical studies will be conducted on the vaccine and will include 150 volunteers over the age of 60 years,” Maxotov added.
Last month, the China Centre for Disease Control and Prevention (CDC) announced that Coronavirus vaccines that are being developed in China may be ready for use by the general public as early as November.
Follow the latest news on Google News
